Trials / Completed
CompletedNCT00882947
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ventavis (Iloprost, BAYQ6256) | Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2009-04-17
- Last updated
- 2009-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00882947. Inclusion in this directory is not an endorsement.